Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Duarte, CaliforniaAges 18 years+ - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Scottsdale, ArizonaAges 18–100 - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05751434RecruitingPhase 2
Exercise therapy for prostate cancer patients on active surveillance
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
Durate, CaliforniaAges 18 years+ - NCT05766371RecruitingPhase 2
Immunotherapy plus targeted radiation for advanced prostate cancer
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05720130RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer found on PSMA scans
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
Brisbane, QueenslandAges 18 years+ - NCT05710380Recruiting
MRI scans to guide biopsy for prostate cancer diagnosis
This study tests whether special MRI “risk maps” can help doctors better identify suspicious areas in the prostate during diagnosis. If you’re having an MRI followed by an MRI-guided biopsy, this may help improve how the biopsy targets areas of concern.
Chicago, IllinoisAges 18 years+ - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05627219Recruiting
Training men to share prostate cancer genetics info
This study tests a program that trains men (especially African American men) to help others understand prostate cancer genetic counseling and testing. It may improve access to this information by using peer support and patient navigation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT05590624Recruiting
Mediterranean diet study for men on prostate cancer active surveillance
This trial studies how different controlled versions of a Mediterranean-style diet may affect prostate cancer-related metabolism in men choosing active surveillance. It may help participants understand whether diet changes influence markers linked to prostate cancer activity, while keeping them on a monitored care plan.
Cleveland, OhioAges 18 years+ - NCT05586360RecruitingPhase 2
Testing how a statin may change immune markers in prostate cancer
This Phase 2 study tests whether taking simvastatin can change “immune regulation” markers in men with intermediate- to high-risk localized prostate cancer. It also looks at whether this could help lower the risk of cancer coming back after planned prostate surgery.
Atlanta, GeorgiaAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Birmingham, AlabamaAges 18–100 - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05530655RecruitingEarly Phase 1
Finding the best lisinopril dose to prevent urine side effects
This early study tests which dose of lisinopril works best to help prevent urinary toxicity (urine/burning/urinary side effects) after radiation treatment for prostate cancer. If it’s effective for you, it could make radiation easier to tolerate.
Rochester, New YorkAges 18–70 - NCT04763317Recruiting
Precision medicine for prostate cancer care decisions
This study tries to personalize prostate cancer care by matching treatment decisions to a person’s specific risk profile. You might be able to join if you have certain types of prostate cancer or a strong family history and meet health-function requirements.
Sutton, EnglandAges 30–70 - NCT05478694Recruiting
Focal ablation outcomes for prostate cancer
This study looks at how well a targeted procedure (“focal ablation,” which destroys only the cancer area) works for certain men with prostate cancer that is limited to the prostate. It may help doctors understand which people benefit most and what outcomes to expect.
Dallas, TexasAges 18–90 - NCT05487846Recruiting
Peer support during genetic testing for metastatic prostate cancer
This trial offers support from a trained peer to help African American men understand and go through genetic testing for prostate cancer. It may help you feel less overwhelmed and better prepared during the testing and decision-making process.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05448547RecruitingPhase 3
Tested curative vs conservative treatment for older men with high-risk prostate cancer
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
CopenhagenAges 75 years+ - NCT05457699RecruitingPhase 2
Targeted radiation to control prostate cancer spread
This Phase 2 study tests whether a focused form of radiation given after your cancer responds to medicine can help keep metastatic prostate cancer under control. It may help by “consolidating” your current good response, potentially delaying progression.
Montreal, QuebecAges Any age - NCT05454488RecruitingPhase 2
Study focal freezing for intermediate-risk prostate cancer
This trial tests whether freezing only the cancer area in the prostate (focal cryotherapy) can control intermediate-risk prostate cancer. It aims to limit treatment to one tumor focus while closely checking results with targeted and follow-up testing.
Houston, TexasAges 18 years+ - NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.